Intracalvariosseous injection bypasses the blood-brain barrier as a novel drug delivery approach for pre-clinical and clinical trials in stroke

Wenqian Liu,Nanxing Wang,Mo Yang,Meiyang Zhang,Xiangrong Liu,Kaibin Shi,Weiming Liu,Yunwei Ou,Liping Liu,Zhonghua Yang,Yanfang Liu,Mengyuan Zhou,Xiaoling Liao,Hui Qu,Fu-Dong Shi,Yuesong Pan,Chaoyu Wang,Xuezheng Feng,Xingquan Zhao,Mingjun Zhang,Yongjun Wang,Yilong Wang
DOI: https://doi.org/10.1101/2024.03.03.24303548
2024-03-24
Abstract:Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely integrity of the blood-brain barrier (BBB) for CNS penetration. Here we showed that the microchannels between the skull marrow and the dura mater could be harnessed for drug delivery by intracalvariosseous (ICO) injection. Drugs administered via ICO injection were found to reach cranial bone marrow-dura-perivascular space, and the injection procedure did not cause osteomyelitis or BBB damage. To validate this approach, we examined the efficacy of two neuroprotective agents, NA-1 and Y-3, via ICO injection in rat model of stroke and found that ICO injection increased drug accumulation in the brain compared to intravenous injection, reduced infarct area and alleviated neurological deficits. We subsequently conducted a clinical trial to assess the safety of ICO in acute ischemic stroke patients ( identifier ), showing that ICO injection was feasible and safe in humans and its therapeutic effects may be observed. Collectively, our study identifies that the microchannels between the skull bone marrow and the dura mater act as a new channel for CNS drug delivery to achieve high intracranial drug exposure in a short period of time. The safety of ICO injection makes it a promising route of drug administration for CNS diseases.
Neurology
What problem does this paper attempt to address?
### Problems the Paper Aims to Solve This paper aims to address the challenge of drug delivery in the treatment of central nervous system (CNS) diseases. Specifically, the presence of the blood-brain barrier (BBB) makes it difficult for most drugs to enter the brain, especially large molecule drugs and biologics such as peptides, proteins, and monoclonal antibodies. To overcome this challenge, researchers have explored a new drug delivery method—Intracalvariosseous (ICO) injection. ### Main Research Content 1. **Feasibility of ICO Injection**: - Researchers conducted experiments in a mouse model to verify that ICO injection can successfully deliver dye molecules (such as Evans blue) into the brain parenchyma. - The experimental results showed that after ICO injection, the concentration of dye in the brain tissue was significantly higher than that of intravenous injection, and it did not cause osteomyelitis or blood-brain barrier damage. 2. **Pathway of ICO Injection**: - Using a fluorescently labeled peptide PSD95 inhibitor NA-1, researchers found that drugs injected via ICO can enter the brain parenchyma through microchannels between the skull and dura mater, thereby bypassing the blood-brain barrier. - This pathway is consistent with the research results of cerebrospinal fluid entering the dura mater through the perivascular space. 3. **Effect of ICO Injection in Stroke Animal Models**: - In a rat stroke model, researchers evaluated the effects of ICO injection of two PSD95 inhibitors (NA-1 and Y-3). - The results showed that the infarct area and neurological deficit scores in the ICO injection group were significantly lower than those in the intravenous injection group, indicating that ICO injection is an effective method for stroke treatment. 4. **Safety of ICO Injection in Clinical Trials**: - Researchers conducted clinical trials to evaluate the safety of ICO injection in patients with acute ischemic stroke. - The clinical trial results showed that ICO injection is simple, safe, and observed to improve patients' neurological function within 14 days. ### Conclusion This study successfully bypassed the blood-brain barrier through the ICO injection method, achieving efficient drug delivery in the brain parenchyma. This method showed good efficacy in stroke animal models and demonstrated safety and potential therapeutic effects in preliminary clinical trials. Therefore, ICO injection is expected to become a new and effective treatment approach for central nervous system diseases.